[go: up one dir, main page]

MA42864B1 - Cyclic ether-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use - Google Patents

Cyclic ether-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

Info

Publication number
MA42864B1
MA42864B1 MA42864A MA42864A MA42864B1 MA 42864 B1 MA42864 B1 MA 42864B1 MA 42864 A MA42864 A MA 42864A MA 42864 A MA42864 A MA 42864A MA 42864 B1 MA42864 B1 MA 42864B1
Authority
MA
Morocco
Prior art keywords
cyclic ether
heterocyclyl
methods
pyrazol
carboxamide compounds
Prior art date
Application number
MA42864A
Other languages
French (fr)
Other versions
MA42864A1 (en
Inventor
Wesley Blackaby
Jason Burch
Alastair Hodges
Andrew Sharpe
Minghua Sun
Xiaojing Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority claimed from PCT/EP2013/069892 external-priority patent/WO2014048939A1/en
Publication of MA42864A1 publication Critical patent/MA42864A1/en
Publication of MA42864B1 publication Critical patent/MA42864B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of formula i, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein r2 is a cyclic ether and x is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting pim kinase, and for treating disorders such as cancer mediated by pim kinase. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of formula i, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein r2 is a cyclic ether and x is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting pim kinase, and for treating disorders such as cancer mediated by pim kinase. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

MA42864A 2012-09-26 2013-09-25 Cyclic ether-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use MA42864B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705791P 2012-09-26 2012-09-26
PCT/EP2013/069892 WO2014048939A1 (en) 2012-09-26 2013-09-25 Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

Publications (2)

Publication Number Publication Date
MA42864A1 MA42864A1 (en) 2019-08-30
MA42864B1 true MA42864B1 (en) 2020-05-29

Family

ID=60450323

Family Applications (2)

Application Number Title Priority Date Filing Date
MA38008A MA38008A1 (en) 2012-09-26 2013-09-25 Cyclic ether-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
MA42864A MA42864B1 (en) 2012-09-26 2013-09-25 Cyclic ether-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA38008A MA38008A1 (en) 2012-09-26 2013-09-25 Cyclic ether-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

Country Status (1)

Country Link
MA (2) MA38008A1 (en)

Also Published As

Publication number Publication date
MA42864A1 (en) 2019-08-30
MA38008A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
PH12015500488A1 (en) Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
MX2014014828A (en) 5-azaindazole compounds and methods of use.
EA201290957A1 (en) PYRAZOL-4-ILHETEROCYCLILKARBOXAMIDE COMPOUNDS AND METHODS OF THEIR APPLICATION
MX2014005285A (en) Bicyclic piperazine compounds.
UA111756C2 (en) HETEROARYLPYRIDONE AND AZAPIRIDONE COMPOUNDS AS BRUTON TYROSINKINASE INHIBITORS
MX2014005282A (en) 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity.
IN2014CN03265A (en)
MY160349A (en) Pyridone and aza-pyridone compounds and methods of use
MX2014001239A (en) PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE.
MX340013B (en) Benzoxazepin compounds selective for pi3k p110 delta and methods of use.
MX2016007171A (en) Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality.
MX2015018038A (en) Heteroaryl pyridone and aza-pyridone amide compounds.
UA116774C2 (en) Serine/threonine kinase inhibitors
MX2020000404A (en) Syk inhibitors.
MX2011009167A (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies.
MX2011012520A (en) Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use.
MA32272B1 (en) Inhibitors of pyrazole [3,4-b] pyridine raf
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
PH12013502369A1 (en) Diazacarbazoles and methods of use
UA112795C2 (en) BICYCLIC PYRAZINONE DERIVATIVES
MX2012006822A (en) 1, 7 - diazacarbazoles and their use in the treatment of cancer.
MX338551B (en) Novel fused pyridine compounds as casein kinase inhibitors.
SG178899A1 (en) Raf inhibitor compounds and methods of use thereof
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
EA201590183A1 (en) AZAINDOL DERIVATIVES PERFORMING AS PI3K INHIBITORS